Get the composition of our in-house portfolios

All portfolios and performance
Portfolio Ref: EQ355LO2W
Performance in the last:
Follow this Portfolio
1D 0.2 %
1W 0.4 %
2W 6.1 %
1M 5.3 %
3M 1.4 %
6M 0.2 %
9M -7.3 %
1Y 3.7 %
Alpha
-3.9%
Beta
0.32
sharpe-R
0.23
Benchmark
SP500 (SPDR S&P 500 ETF Trust)
sharpe-R Benchmark
1.87
The portfolio metrics Alpha, Beta and Sharpe Ratio are computed using a risk free rate of 0%.
Other Information
Calculation Frequency Daily
Latest Valuation Time 2025-01-31 07:53:38
Launch Date 2023-01-01 00:00:00
First Valuation Date 2021-01-01 00:00:00
Max. DrawDown -13.4%
Max. DrawDown Benchmark -8.41%

This Long Only strategy aims to find promising assets to invest in for a maximum holding period of 2 Weeks in the Equity asset class. This portfolio focuses only on companies in the Health Care sector. The maximum number of assets that can be allocated in this strategy is 5.

The assets selection in this portfolio is based on: Macro-Pattern Mix St..
Please note that all model portfolios assume that the entry price for each trade is the previous close price.

Portfolio Performance against the market Benchmark

Try Our Peformance Checker Tool

Risk Level
4
Difficulty Level
2

Do you want to invest in this strategy ?

Follow the portfolio and you will get notified for every change in the composition of the portfolio

Current Portfolio Composition

Asset Asset Class Action Weight PnL
GKOS Glaukos Corporation Equity Buy 18.79% 0.87%
NTRA Natera, Inc. Equity Buy 19.8% 0%
The percentage of cash held in the portfolio is: 61.41%
** The description of each asset is available Here

The latest 5 Compositions change

2025-01-31 00:00:00 : Portfolio change date
Asset Action Weight PnL
GKOS Glaukos Corporation Buy 18.79% 0.87%
NTRA Natera, Inc. Buy 19.8% 0%
The percentage of cash held in the portfolio is: 61.41%
New Assets Added
  • NTRA
Assets Removed
Asset Action Perf %
DNLI Sell All 8.81%
Assets Rebalanced
None
2025-01-30 00:00:00 : Portfolio change date
Asset Action Weight PnL
DNLI Denali Therapeutics Inc. Buy 20.1% 8.03%
GKOS Glaukos Corporation Buy 18.94% 1.68%
The percentage of cash held in the portfolio is: 60.96%
New Assets Added
None
Assets Removed
Asset Action Perf %
AXSM Sell All 12.15%
INSM Sell All 11.11%
Assets Rebalanced
None
2025-01-21 00:00:00 : Portfolio change date
Asset Action Weight PnL
AXSM Axsome Therapeutics, Inc. Buy 19.35% -1.94%
INSM Insmed Incorporated Buy 20.38% 3.29%
DNLI Denali Therapeutics Inc. Buy 19.95% 1.2%
GKOS Glaukos Corporation Buy 19.75% 0%
The percentage of cash held in the portfolio is: 20.56%
New Assets Added
None
Assets Removed
Asset Action Perf %
TNDM Sell All NA
Assets Rebalanced
None
2025-01-20 00:00:00 : Portfolio change date
Asset Action Weight PnL
TNDM Tandem Diabetes Care, Inc. Buy 18.56% -5.9%
AXSM Axsome Therapeutics, Inc. Buy 19.35% -1.94%
INSM Insmed Incorporated Buy 20.38% 3.29%
DNLI Denali Therapeutics Inc. Buy 19.95% 1.2%
GKOS Glaukos Corporation Buy 19.75% 0%
The percentage of cash held in the portfolio is: 2%
New Assets Added
  • GKOS
Assets Removed
None
Assets Rebalanced
None
2025-01-17 00:00:00 : Portfolio change date
Asset Action Weight PnL
TNDM Tandem Diabetes Care, Inc. Buy 19.54% 0.47%
AXSM Axsome Therapeutics, Inc. Buy 19.44% -0.06%
INSM Insmed Incorporated Buy 20.16% 3.63%
DNLI Denali Therapeutics Inc. Buy 19.43% 0%
The percentage of cash held in the portfolio is: 21.43%
New Assets Added
  • DNLI
Assets Removed
None
Assets Rebalanced
None
2025-01-16 00:00:00 : Portfolio change date
Asset Action Weight PnL
TNDM Tandem Diabetes Care, Inc. Buy 19% -3.76%
AXSM Axsome Therapeutics, Inc. Buy 19.75% 0%
INSM Insmed Incorporated Buy 19.75% 0%
The percentage of cash held in the portfolio is: 41.5%
New Assets Added
  • AXSM
  • INSM
Assets Removed
None
Assets Rebalanced
None
2025-01-07 00:00:00 : Portfolio change date
Asset Action Weight PnL
TNDM Tandem Diabetes Care, Inc. Buy 19.6% 0%
The percentage of cash held in the portfolio is: 80.4%
New Assets Added
  • TNDM
Assets Removed
None
Assets Rebalanced
None
2024-12-11 00:00:00 : Portfolio change date
No Asset in the portfolio
The percentage of cash held in the portfolio is: 100%
New Assets Added
None
Assets Removed
Asset Action Perf %
APLS Sell All 6.16%
Assets Rebalanced
None
2024-12-05 00:00:00 : Portfolio change date
Asset Action Weight PnL
APLS Apellis Pharmaceuticals, Inc. Buy 20.79% 4.6%
The percentage of cash held in the portfolio is: 79.21%
New Assets Added
None
Assets Removed
Asset Action Perf %
ARWR Sell All -11.63%
Assets Rebalanced
None
2024-11-28 00:00:00 : Portfolio change date
Asset Action Weight PnL
APLS Apellis Pharmaceuticals, Inc. Buy 20.32% 4.63%
ARWR Arrowhead Pharmaceuticals, Inc. Buy 19.42% 0%
The percentage of cash held in the portfolio is: 60.26%
New Assets Added
  • ARWR
Assets Removed
None
Assets Rebalanced
None
2024-11-27 00:00:00 : Portfolio change date
Asset Action Weight PnL
APLS Apellis Pharmaceuticals, Inc. Buy 19.6% 0%
The percentage of cash held in the portfolio is: 80.4%
New Assets Added
  • APLS
Assets Removed
None
Assets Rebalanced
None
2024-11-21 00:00:00 : Portfolio change date
No Asset in the portfolio
The percentage of cash held in the portfolio is: 100%
New Assets Added
None
Assets Removed
Asset Action Perf %
HUM Sell All 1.89%
Assets Rebalanced
None
2024-11-19 00:00:00 : Portfolio change date
Asset Action Weight PnL
HUM Humana Inc. Buy 19.09% -5.95%
The percentage of cash held in the portfolio is: 80.91%
New Assets Added
None
Assets Removed
Asset Action Perf %
IRTC Sell All -5.62%
CORT Sell All 5.11%
Assets Rebalanced
None
2024-11-18 00:00:00 : Portfolio change date
Asset Action Weight PnL
IRTC iRhythm Technologies, Inc. Buy 19.98% -1.22%
CORT Corcept Therapeutics Incorporated Buy 20.94% 3.54%
HUM Humana Inc. Buy 19.22% -4.45%
The percentage of cash held in the portfolio is: 39.86%
New Assets Added
None
Assets Removed
Asset Action Perf %
RGEN Sell All -17.11%
Assets Rebalanced
None
2024-11-14 00:00:00 : Portfolio change date
Asset Action Weight PnL
IRTC iRhythm Technologies, Inc. Buy 20.03% 6.99%
CORT Corcept Therapeutics Incorporated Buy 21.11% 12.76%
HUM Humana Inc. Buy 18.68% 0.32%
RGEN Repligen Corporation Buy 19.08% 0%
The percentage of cash held in the portfolio is: 21.08%
New Assets Added
  • RGEN
Assets Removed
Asset Action Perf %
INCY Sell All 8.86%
IART Sell All -6.42%
Assets Rebalanced
None

Load more previous compositions

Compositions In The Last 2W Compositions In The Last 1M Compositions In The Last 3M Compositions In The Last 6M

Market Overview

Disclaimer Quantam Research does not provide personal investment or financial advice to individuals, or act as personal financial, legal, or institutional investment advisors, or individually advocate the purchase or sale of any security or investment or the use of any particular financial strategy. All investing, assets forecasts and investment strategies include the risk of loss for some or even all of your capital. Before pursuing any financial strategies discussed on this website, you should always consult with a licensed financial advisor.
Cookies Settings